Tvardi Therapeutics
TVRD
60 hedge funds and large institutions have $112M invested in Tvardi Therapeutics in 2015 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 26 increasing their positions, 11 reducing their positions, and 4 closing their positions.
136% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 11
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
8% more capital invested
Capital invested by funds: $104M → $112M (+$8.65M)
7% more funds holding
Funds holding: 56 → 60 (+4)
3.32% more ownership
Funds ownership: 45.53% → 48.85% (+3.3%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$3.69M |
| 2 |
Renaissance Technologies
New York
|
+$2.62M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.47M |
| 4 |
Millennium Management
New York
|
+$1.98M |
| 5 |
CPM
Chesapeake Partners Management
Baltimore,
Maryland
|
+$955K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DPA
Devon Park Associates
|
-$5.84M |
| 2 |
HP
Harbourvest Partners
Boston,
Massachusetts
|
-$672K |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$595K |
| 4 |
JP Morgan Chase
New York
|
-$437K |
| 5 |
HLA
Hamilton Lane Advisors
Conshohocken,
Pennsylvania
|
-$210K |
TVRD Hedge Fund Activity: Q1 2015 in Review
60 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q1 2015, worth a combined $112M — up 8.4% from $104M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new TVRD positions and 4 closed out — a net gain of 4 holders — while 26 added to existing stakes and 11 trimmed.
The largest buyer was TFS Capital, adding an estimated $3.69M. The largest seller was Devon Park Associates, cutting an estimated $5.84M.
- 60 institutional investors held Tvardi Therapeutics (TVRD) as of Q1 2015, up from 56 in Q4 2014.
- Funds reported $112M of Tvardi Therapeutics stock for Q1 2015, up 8.4% quarter-over-quarter.
- 8 funds opened new Tvardi Therapeutics positions in Q1 2015 and 4 closed out, a net change of +4 holders.
- The largest Tvardi Therapeutics buyer in Q1 2015 was TFS Capital, an estimated $3.69M added.
- The largest Tvardi Therapeutics seller in Q1 2015 was Devon Park Associates, an estimated $5.84M sold.
Based on aggregated 13F filings for Q1 2015.